Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / COM NEW
-
Number of holders
-
66
-
Total 13F shares, excl. options
-
7,287,350
-
Shares change
-
-629,654
-
Total reported value, excl. options
-
$28,239,646
-
Value change
-
-$2,237,797
-
Put/Call ratio
-
61.5%
-
Number of buys
-
19
-
Number of sells
-
-35
-
Price
-
$3.88
Significant Holders of GALECTIN THERAPEUTICS INC - COM NEW (GALT) as of Q3 2021
85 filings reported holding GALT - GALECTIN THERAPEUTICS INC - COM NEW as of Q3 2021.
GALECTIN THERAPEUTICS INC - COM NEW (GALT) has 66 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 7,287,350 shares
.
Largest 10 shareholders include VANGUARD GROUP INC (1,953,419 shares), ADVISOR GROUP HOLDINGS, INC. (1,273,957 shares), BlackRock Inc. (787,582 shares), GEODE CAPITAL MANAGEMENT, LLC (540,866 shares), Geneos Wealth Management Inc. (491,367 shares), MILLENNIUM MANAGEMENT LLC (350,336 shares), Cutter & CO Brokerage, Inc. (184,742 shares), Cambridge Investment Research Advisors, Inc. (164,498 shares), STATE STREET CORP (158,759 shares), and Ergoteles LLC (136,320 shares).
This table shows the top 66 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.